• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

嵌合抗原受体信号域对病毒特异性T细胞的增殖和天然T细胞受体功能有不同的调节作用。

Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells.

作者信息

Omer Bilal, Castillo Paul A, Tashiro Haruko, Shum Thomas, Huynh Mai T A, Cardenas Mara, Tanaka Miyuki, Lewis Andrew, Sauer Tim, Parihar Robin, Lapteva Natalia, Schmueck-Henneresse Michael, Mukherjee Malini, Gottschalk Stephen, Rooney Cliona M

机构信息

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital, Houston, TX, United States.

Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States.

出版信息

Front Med (Lausanne). 2018 Dec 11;5:343. doi: 10.3389/fmed.2018.00343. eCollection 2018.

DOI:10.3389/fmed.2018.00343
PMID:30619856
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6297364/
Abstract

The efficacy of T cells expressing chimeric antigen receptors (CARs) for solid tumors has been limited by insufficient CAR T cell expansion and persistence. The use of virus-specific T cells (VSTs) as carriers for CARs may overcome this limitation since CAR-VSTs can be boosted by viral vaccines or oncolytic viruses. However, there is limited understanding of the optimal combination of endodomains and their influence on the native T cell receptor (TCR) in VSTs. We therefore compared the function of GD2.CARs expressing the TCR zeta chain (ζ) alone or combined with endodomains from CD28 and 4-1BB in varicella zoster virus-specific (VZV) T cells. VZVSTs expressing GD2-CARs recognized VZV-derived peptides and killed GD2-expressing tumor cells. However, after repeated stimulation through their native TCR, the expansion of GD2-CAR.CD28ζ-VZVSTs was 3.3-fold greater ( < 0.001) than non-transduced VZVSTs, whereas GD2-CARζ- and GD2-CAR.41BBζ inhibited VZVST expansion ( < 0.01). Compared to control VZVSTs, GD2-CAR.ζ VZVSTs showed a greater frequency of apoptotic ( < 0.01) T cells, whereas prolonged downregulation of the native αβ TCR was observed in GD2-CAR.41BBζ VZVSTs ( < 0.001). We confirmed that CD28ζ can best maintain TCR function by expressing GD2.CARs in Epstein-Barr virus-specific T cells and CD19-CARs in VZVSTs. In response to CAR stimulation VSTs with CD28ζ endodomains also showed the greatest expansion (6 fold > GD2-CAR.41BBζ VZVSTs ( < 0.001), however anti-tumor efficacy was superior in GD2-CAR.41BBζ-VZVSTs. These findings demonstrate that CAR signaling domains can enhance or diminish the function of the native TCR and indicate that only CD28ζ may preserve the function of the native TCR in tonically signaling CAR-VSTs.

摘要

表达嵌合抗原受体(CAR)的T细胞对实体瘤的疗效受到CAR T细胞扩增不足和持久性的限制。使用病毒特异性T细胞(VST)作为CAR的载体可能会克服这一限制,因为CAR-VST可以通过病毒疫苗或溶瘤病毒得到增强。然而,对于VST中胞内结构域的最佳组合及其对天然T细胞受体(TCR)的影响,人们了解有限。因此,我们比较了单独表达TCR ζ链(ζ)或与来自CD28和4-1BB的胞内结构域组合的GD2.CAR在水痘带状疱疹病毒特异性(VZV)T细胞中的功能。表达GD2-CAR的VZVST识别VZV衍生的肽并杀死表达GD2的肿瘤细胞。然而,在通过其天然TCR反复刺激后,GD2-CAR.CD28ζ-VZVST的扩增比未转导的VZVST大3.3倍(<0.001),而GD2-CARζ-和GD2-CAR.41BBζ抑制VZVST的扩增(<0.01)。与对照VZVST相比,GD2-CAR.ζ VZVST显示出更高频率的凋亡T细胞(<0.01),而在GD2-CAR.41BBζ VZVST中观察到天然αβ TCR的长期下调(<0.001)。我们证实,通过在爱泼斯坦-巴尔病毒特异性T细胞中表达GD2.CAR和在VZVST中表达CD19-CAR,CD28ζ能够最好地维持TCR功能。在CAR刺激下,具有CD28ζ胞内结构域的VST也显示出最大的扩增(比GD2-CAR.41BBζ VZVST大6倍(<0.001)),然而GD2-CAR.41BBζ-VZVST的抗肿瘤疗效更优。这些发现表明,CAR信号结构域可以增强或减弱天然TCR的功能,并表明只有CD28ζ可能在持续信号传导的CAR-VST中保留天然TCR的功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168c/6297364/1b8fa092e6c3/fmed-05-00343-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168c/6297364/9e0ab06c6777/fmed-05-00343-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168c/6297364/903d134ba6dd/fmed-05-00343-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168c/6297364/47e34127d43f/fmed-05-00343-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168c/6297364/cf3067d5a976/fmed-05-00343-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168c/6297364/1b8fa092e6c3/fmed-05-00343-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168c/6297364/9e0ab06c6777/fmed-05-00343-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168c/6297364/903d134ba6dd/fmed-05-00343-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168c/6297364/47e34127d43f/fmed-05-00343-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168c/6297364/cf3067d5a976/fmed-05-00343-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/168c/6297364/1b8fa092e6c3/fmed-05-00343-g0005.jpg

相似文献

1
Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells.嵌合抗原受体信号域对病毒特异性T细胞的增殖和天然T细胞受体功能有不同的调节作用。
Front Med (Lausanne). 2018 Dec 11;5:343. doi: 10.3389/fmed.2018.00343. eCollection 2018.
2
Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.针对天然受体的疫苗接种以增强嵌合抗原受体 (CAR) 修饰的 T 细胞的功能和增殖。
Clin Cancer Res. 2017 Jul 15;23(14):3499-3509. doi: 10.1158/1078-0432.CCR-16-2138. Epub 2017 Feb 9.
3
Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.早期转导产生具有中央记忆标志物的高功能嵌合抗原受体修饰的病毒特异性 T 细胞:细胞治疗的生产助理(PACT)的转化应用。
J Immunother Cancer. 2015 Feb 18;3:5. doi: 10.1186/s40425-015-0049-1. eCollection 2015.
4
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.嵌合抗原受体修饰的不变自然杀伤 T 细胞为安全有效的肿瘤免疫治疗提供了新平台。
Blood. 2014 Oct 30;124(18):2824-33. doi: 10.1182/blood-2013-11-541235. Epub 2014 Jul 21.
5
Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.表达自杀基因和靶向信号淋巴细胞激活分子 F7 的嵌合抗原受体的 CAR T 细胞的开发。
Mol Ther. 2021 Feb 3;29(2):702-717. doi: 10.1016/j.ymthe.2020.10.008. Epub 2020 Oct 14.
6
4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.4-1BB 共刺激和优化的 CD28 共刺激增强了人单特异性和双特异性第三代 CAR T 细胞的功能。
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003354.
7
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced Persistence and Antitumor Activity against Neuroblastoma.同时表达 GD2 特异性嵌合抗原受体和 IL15 的 NKT 细胞对神经母细胞瘤表现出增强的持久性和抗肿瘤活性。
Clin Cancer Res. 2019 Dec 1;25(23):7126-7138. doi: 10.1158/1078-0432.CCR-19-0421. Epub 2019 Sep 4.
8
Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.不同的细胞因子和刺激条件会影响针对肿瘤抗原GD2的第三代嵌合抗原受体T细胞的扩增和免疫表型。
Cytotherapy. 2015 Apr;17(4):487-95. doi: 10.1016/j.jcyt.2014.12.002. Epub 2015 Jan 6.
9
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.一种新型抗GD2/4-1BB嵌合抗原受体可触发神经母细胞瘤细胞杀伤。
Oncotarget. 2015 Sep 22;6(28):24884-94. doi: 10.18632/oncotarget.4670.
10
CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.CD171 和 GD2 特异性 CAR-T 细胞在临床前体外试验中强烈靶向视网膜母细胞瘤细胞。
BMC Cancer. 2019 Sep 9;19(1):895. doi: 10.1186/s12885-019-6131-1.

引用本文的文献

1
Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context.无同种异体反应性的嵌合抗原受体病毒特异性T细胞疗法:病毒背景下长期肿瘤控制的一大进步。
Front Immunol. 2025 Jan 15;15:1527648. doi: 10.3389/fimmu.2024.1527648. eCollection 2024.
2
GD2-targeting therapy: a comparative analysis of approaches and promising directions.靶向 GD2 的治疗方法:方法比较分析及有前景的方向。
Front Immunol. 2024 Mar 15;15:1371345. doi: 10.3389/fimmu.2024.1371345. eCollection 2024.
3
The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer.

本文引用的文献

1
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.嵌合抗原受体中 4-1BB 共刺激会阻碍 T 细胞存活,且具有载体依赖性。
Cell Rep. 2017 Oct 3;21(1):17-26. doi: 10.1016/j.celrep.2017.09.015.
2
Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.鉴定CD3和CD28抗体激活的嵌合抗原受体修饰T细胞的T细胞亚群起源的综合方法
J Immunol. 2017 Jul 1;199(1):348-362. doi: 10.4049/jimmunol.1601494. Epub 2017 May 26.
3
Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.
免疫细胞疗法治疗癌症的进展与前景
Cell Transplant. 2024 Jan-Dec;33:9636897241231892. doi: 10.1177/09636897241231892.
4
Joining Forces for Cancer Treatment: From "TCR versus CAR" to "TCR and CAR".联合力量治疗癌症:从“TCR 与 CAR”到“TCR 和 CAR”。
Int J Mol Sci. 2022 Nov 23;23(23):14563. doi: 10.3390/ijms232314563.
5
A Costimulatory CAR Improves TCR-based Cancer Immunotherapy.共刺激 CAR 可改善基于 TCR 的癌症免疫疗法。
Cancer Immunol Res. 2022 Apr 1;10(4):512-524. doi: 10.1158/2326-6066.CIR-21-0307.
6
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.T 细胞受体刺激增强表达嵌合抗原受体的 CD19 T 细胞的扩增和功能。
Clin Cancer Res. 2019 Dec 15;25(24):7340-7350. doi: 10.1158/1078-0432.CCR-18-3199. Epub 2019 Sep 26.
7
Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors.工程学助力成功:改善嵌合抗原受体 T 细胞疗法治疗实体瘤的方法。
Drugs. 2019 Mar;79(4):401-415. doi: 10.1007/s40265-019-01071-7.
针对天然受体的疫苗接种以增强嵌合抗原受体 (CAR) 修饰的 T 细胞的功能和增殖。
Clin Cancer Res. 2017 Jul 15;23(14):3499-3509. doi: 10.1158/1078-0432.CCR-16-2138. Epub 2017 Feb 9.
4
CD28 Costimulation: From Mechanism to Therapy.CD28共刺激:从机制到治疗
Immunity. 2016 May 17;44(5):973-88. doi: 10.1016/j.immuni.2016.04.020.
5
Chimeric antigen receptor T-cell therapy for solid tumors.嵌合抗原受体 T 细胞疗法治疗实体瘤。
Mol Ther Oncolytics. 2016 Apr 13;3:16006. doi: 10.1038/mto.2016.6. eCollection 2016.
6
Control of T cell antigen reactivity via programmed TCR downregulation.通过程序性TCR下调来控制T细胞抗原反应性。
Nat Immunol. 2016 Apr;17(4):379-86. doi: 10.1038/ni.3386. Epub 2016 Feb 22.
7
Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.记忆性T细胞驱动的幼稚细胞分化会损害过继性免疫疗法。
J Clin Invest. 2016 Jan;126(1):318-34. doi: 10.1172/JCI81217. Epub 2015 Dec 14.
8
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.工程共刺激结构设计决定肿瘤排斥动力学和 CAR T 细胞的持久性。
Cancer Cell. 2015 Oct 12;28(4):415-428. doi: 10.1016/j.ccell.2015.09.004.
9
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.源自特定CD8+和CD4+亚群的嵌合抗原受体修饰的T细胞在体内具有更强的抗肿瘤反应性。
Leukemia. 2016 Feb;30(2):492-500. doi: 10.1038/leu.2015.247. Epub 2015 Sep 15.
10
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.4-1BB共刺激可改善嵌合抗原受体的持续性信号传导所诱导的T细胞耗竭。
Nat Med. 2015 Jun;21(6):581-90. doi: 10.1038/nm.3838. Epub 2015 May 4.